Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study
Rev Esp Cardiol (Engl Ed). 2019 Feb;72(2):167-169.
doi: 10.1016/j.rec.2017.11.025.
Epub 2018 Jan 17.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Cardiología, Hospital General Universitario de Castellón, Universitat Jaume I, Castellón, Spain.
- 2 Servicio de Cardiología, Hospital Clínico Universitario, Instituto de Investigación Sanitaria (INCLIVA), Valencia, Spain.
- 3 Servicio de Cardiología, Hospital Clínico Universitario, Instituto de Investigación Sanitaria (INCLIVA), Valencia, Spain; Departamento de Medicina, Universitat de València, Valencia, Spain; CIBER Cardiovascular, Madrid, Spain.
- 4 CIBER Cardiovascular, Madrid, Spain; Servicio de Cardiología y Unidad de Insuficiencia Cardiaca, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
- 5 Servicio de Cardiología, Hospital Clínico Universitario, Instituto de Investigación Sanitaria (INCLIVA), Valencia, Spain; Departamento de Medicina, Universitat de València, Valencia, Spain; CIBER Cardiovascular, Madrid, Spain. Electronic address: yulnunez@gmail.com.
No abstract available
MeSH terms
-
Aged
-
Aminobutyrates / therapeutic use*
-
Angiotensin Receptor Antagonists / therapeutic use
-
Biphenyl Compounds
-
Drug Combinations
-
Exercise Tolerance / drug effects*
-
Female
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Humans
-
Male
-
Neprilysin
-
Pilot Projects
-
Stroke Volume / physiology*
-
Tetrazoles / therapeutic use*
-
Treatment Outcome
-
Valsartan
Substances
-
Aminobutyrates
-
Angiotensin Receptor Antagonists
-
Biphenyl Compounds
-
Drug Combinations
-
Tetrazoles
-
Valsartan
-
Neprilysin
-
sacubitril and valsartan sodium hydrate drug combination